Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
FDA signs off on AZ spinout Dizal's lung cancer drug Zegfrovy
Dizal has gained its first FDA approval, winning an accelerated nod for Zegfrovy to become the only oral treatment for those with a rare type of NSCLC.
Kevin Dunleavy
Jul 7, 2025 11:28am
FDA signs off on AZ, Daiichi's Datroway for EGFR-mutated NSCLC
Jun 24, 2025 8:10am
AbbVie, ADCs and the future of cancer care
Jun 20, 2025 9:39am
With lung cancer FDA nod, it's David versus Goliath
Jun 11, 2025 4:17pm
ASCO: Bristol CMO brushes off LAG-3 concern after melanoma flop
Jun 3, 2025 8:00am
Summit shares results from ivonescimab's first global ph. 3 trial
May 30, 2025 9:04am
